Cargando…

Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials

BACKGROUND: Prostate cancer is one of the most common cancers in the world. The results of treatment after hypofractionated radiotherapy only have been reported from several small randomized clinical trials. Therefore, we conducted a meta-analysis to compare clinical outcomes of hypofractionated rad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Wei, Sun, Yun-Chuan, Bi, Jian-Qiang, He, Xin-Ying, Xiao, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839052/ https://www.ncbi.nlm.nih.gov/pubmed/31703647 http://dx.doi.org/10.1186/s12885-019-6285-x

Ejemplares similares

Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer
por: Yamazaki, Hideya, et al.
Publicado: (2021)

Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer
por: Soni, Abhishek, et al.
Publicado: (2022)

Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer
por: He, Jiaoxue, et al.
Publicado: (2023)

Hypofractionated Radiotherapy in Localized, Low–Intermediate-Risk Prostate Cancer: Current and Future Prospectives
por: Lo Greco, Maria Chiara, et al.
Publicado: (2023)

Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from Phase III randomized trials
por: Yin, Zhenzhen, et al.
Publicado: (2019)

Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis
por: Di Franco, Rossella, et al.
Publicado: (2017)

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
por: Kim, Hun Jung, et al.
Publicado: (2016)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer
por: Phak, Jeong Hoon, et al.
Publicado: (2016)

Hypofractionated radiotherapy versus conventional radiotherapy for diffuse intrinsic pontine glioma: A systematic review and meta-analysis
por: Park, Jaehyeon, et al.
Publicado: (2020)

Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a secondary analysis from a randomized study
por: Sanguineti, Giuseppe, et al.
Publicado: (2019)

Hypofractionated Radiotherapy in Intermediate-Risk Prostate Cancer Patients: Long-Term Results
por: Valeriani, Maurizio, et al.
Publicado: (2022)

Review of Hypofractionated Radiotherapy for Prostate Cancer
por: Spyropoulou, Despina, et al.
Publicado: (2012)

The Role of Hypofractionated Radiotherapy in Prostate Cancer
por: Benjamin, Linus C., et al.
Publicado: (2017)

Are we ready to use hypofractionated instead of conventional radiotherapy for prostate cancer? Not yet
Publicado: (2019)

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Hypofractionated External-Beam Radiotherapy for Prostate Cancer
por: Cho, L. Chinsoo, et al.
Publicado: (2013)

Moderate hypofractionated radiotherapy is more effective and safe for localized prostate cancer patients: a meta-analysis
por: Cao, Ling, et al.
Publicado: (2016)

Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer: a phase II randomized trial from China
por: Zhong, Qiu-Zi, et al.
Publicado: (2021)

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
por: Wilkins, Anna, et al.
Publicado: (2015)

Comparison of Treatment Outcome between Hypofractionated Radiotherapy and Conventional Radiotherapy in Postmastectomy Breast Cancer
por: Tovanabutra, Chokaew, et al.
Publicado: (2020)

Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: Toxicity analysis
por: Kim, Dong-Yun, et al.
Publicado: (2020)

The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: early results of a randomized trial
por: Alexidis, Petros, et al.
Publicado: (2019)

Conventional Versus Different Hypofractionated Radiotherapy Dosage Schedules in Postmastectomy Advanced Breast Cancer
por: Jain, Neeraj, et al.
Publicado: (2022)

Phase II Trial of Pure Hypofractionated Radiotherapy in the Treatment of Localized Carcinoma of the Prostate
por: Gopaul, Darin, et al.
Publicado: (2018)

Long-Term Outcomes of Dose-Escalated Hypofractionated Radiotherapy in Localized Prostate Cancer
por: Lazo, Antonio, et al.
Publicado: (2022)

Automated prediction of dosimetric eligibility for hypofractionated prostate radiotherapy
por: Lausch, Anthony, et al.
Publicado: (2017)

Late results of a randomized trial on the role of mild hypofractionated radiotherapy for the treatment of localized prostate cancer
por: Alexidis, Petros, et al.
Publicado: (2020)

Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity
por: Chitapanarux, Imjai, et al.
Publicado: (2019)

Local Dose Effects for Late Gastrointestinal Toxicity After Hypofractionated and Conventionally Fractionated Modern Radiotherapy for Prostate Cancer in the HYPRO Trial
por: Heemsbergen, Wilma D., et al.
Publicado: (2020)

Hypofractionated Radiotherapy as Local Hemostatic Agent in Advanced Cancer
por: Rasool, Malik Tariq, et al.
Publicado: (2011)

Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer
por: Crane, Christopher H.
Publicado: (2016)

Hypofractionated Proton Boost Combined with External Beam Radiotherapy for Treatment of Localized Prostate Cancer
por: Johansson, Silvia, et al.
Publicado: (2012)

Hypofractionated intensity-modulated radiotherapy in patients with localized prostate cancer: a preliminary study
por: Kang, Hye Jin, et al.
Publicado: (2016)

Comparison  of  efficacy, safety, and costs between neoadjuvant hypofractionated radiotherapy and conventionally fractionated radiotherapy for esophageal carcinoma
por: Lyu, Jiahua, et al.
Publicado: (2019)

Intrafraction Prostate Motion Management for Ultra-Hypofractionated Radiotherapy of Prostate Cancer
por: Oehler, Christoph, et al.
Publicado: (2022)

Hypofractionated Stereotactic Radiotherapy for Patients with Intracranial Meningiomas: impact of radiotherapy regimen on local control
por: Meniai-Merzouki, F., et al.
Publicado: (2018)

Evolution of Hypofractionated Accelerated Radiotherapy for Prostate Cancer – The Sunnybrook Experience
por: Musunuru, Hima Bindu, et al.
Publicado: (2014)

Hypofractionated Postoperative Radiotherapy for Prostate Cancer: Is the Field Ready Yet?
por: Mahase, Sean, et al.
Publicado: (2020)

Practical Guidelines on Implementing Hypofractionated Radiotherapy for Prostate Cancer in Africa
por: Swanson, William, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t3jholf4aepr2ia6c6a16al267